Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Capital Expenditures (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Capital Expenditures for 7 consecutive years, with $106000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 88.68% to $106000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 88.71% decrease, with the full-year FY2025 number at $1.4 million, down 88.71% from a year prior.
  • Capital Expenditures was $106000.0 for Q4 2025 at Kymera Therapeutics, down from $181000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $11.6 million in Q4 2023 to a low of -$189000.0 in Q3 2024.
  • A 5-year average of $2.7 million and a median of $660500.0 in 2021 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: soared 3016.62% in 2023, then tumbled 102.34% in 2024.
  • Kymera Therapeutics' Capital Expenditures stood at $501000.0 in 2021, then dropped by 25.55% to $373000.0 in 2022, then skyrocketed by 3016.62% to $11.6 million in 2023, then crashed by 91.95% to $936000.0 in 2024, then crashed by 88.68% to $106000.0 in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Capital Expenditures are $106000.0 (Q4 2025), $181000.0 (Q3 2025), and $695000.0 (Q2 2025).